Have you ever watched a stock sector take a nosedive and wondered if it’s time to jump in or steer clear? That’s exactly where health care stocks sit right now, after a brutal May that left investors scratching their heads. The Health Care Select Sector SPDR Fund, known by its ticker XLV, dropped over 5% last month while the broader market soared. But here’s the kicker: historical data and technical charts are flashing signs of a potential rebound in June. Let’s dive into why this beaten-down sector might just be the opportunity you’ve been waiting for.
A Rough Patch for Health Care: What Happened?
Last month was a bloodbath for health care stocks. While the S&P 500 climbed over 6%, XLV lagged behind, underperforming the index by a staggering 11%. That’s not just a bad month—it’s the worst relative performance for XLV since its inception in 1998. Ouch. But here’s where it gets interesting: such extreme underperformance rarely persists. In my experience, when a sector gets hammered this hard, it often sets the stage for a comeback. So, what’s driving this optimism for June?
Technical Signals Point to a Rebound
Charts don’t lie, and right now, they’re screaming opportunity for XLV. The fund has hit two critical support levels that could act as a springboard for a bounce. First, there’s a long-term rising trendline that stretches back to the 2009 financial crisis and connects through the Covid-19 lows. XLV tested this line in mid-May, held firm, and even managed a modest recovery by month’s end. Second, a horizontal support zone in the low 120s—formed by lows in 2021, 2022, and 2023—adds another layer of strength.
When a stock or sector hits a confluence of support levels, it’s like a safety net for investors. The odds of a bounce increase significantly.
– Technical analyst
These converging support lines create what traders call a confluence zone—a sweet spot where buyers often step in. If history is any guide, this setup could spark a rally in June. But a sector ETF like XLV doesn’t move on technicals alone. Its top holdings need to pull their weight, and that’s where the real story unfolds.
The Heavyweights: Can Eli Lilly, JNJ, and AbbVie Deliver?
Here’s a surprising stat: 34 of XLV’s 61 components actually posted gains in May. That’s a silver lining, but the ETF’s performance hinges on its biggest players. Eli Lilly, Johnson & Johnson, and AbbVie make up nearly 27% of the fund’s weight. If these giants don’t rally, XLV could stay stuck in the mud. Let’s break down their prospects.
Eli Lilly: The Big Dog
With a 12% weighting, Eli Lilly is XLV’s top holding. This pharma giant hit an all-time high in August 2024 but shed 30% by April 2025. Talk about a rollercoaster! Since then, it’s been trading in a downward-sloping channel, with sharp declines followed by equally sharp bounces. After a 20% drop from late April to late May, the stock has quietly climbed for six of the last seven trading days. That’s a promising start.
Even better, Eli Lilly’s weekly Williams %R indicator is moving out of oversold territory. This technical signal has preceded major up-moves in the past. If the stock can break above its channel’s upper resistance, we could see a significant rally. For now, the chart suggests it’s primed for at least a short-term pop.
Johnson & Johnson: The Steady Veteran
Johnson & Johnson, with a 7.7% weighting, has been in a slow decline since its 2022 peak. Its chart shows a series of lower highs and lower lows, but it’s now approaching a key support level within its long-term trading channel. This could be the moment for a reversal. I’ve always admired JNJ’s resilience—its diversified portfolio makes it a cornerstone of the health care sector. A bounce here feels like a safe bet.
AbbVie: The Uptrend Star
AbbVie, holding a 6.8% weight, is the outlier. Unlike its peers, it’s been in a clear uptrend for years. However, it’s not immune to pullbacks, and it’s down from its 2025 highs. The stock’s current position near the lower end of its trading channel suggests it’s due for a bounce. AbbVie’s strong fundamentals and consistent performance make it a name to watch.
Why Rotation Matters in Today’s Market
Ever wonder why some sectors shine while others languish? It’s all about market rotation. When high-flying sectors like tech or consumer discretionary start to wobble, capital often flows into underperforming areas like health care. This dynamic is a hallmark of healthy, long-term bull markets. With XLV at a technical crossroads and its top holdings showing signs of life, the stage is set for a potential influx of cash.
- Historical precedent: Extreme underperformance often precedes sharp recoveries.
- Technical support: XLV’s confluence of support levels boosts confidence.
- Heavyweight momentum: Early gains in Eli Lilly and others could spark broader sector strength.
But let’s be real—markets are unpredictable. While the setup looks promising, investors need to stay nimble. Keeping an eye on broader market trends and sector rotation will be key to timing this opportunity.
How to Play the Health Care Rebound
So, how do you capitalize on this potential turnaround? Here are a few strategies to consider, based on the current setup:
- Buy the ETF: XLV offers broad exposure to the health care sector, reducing single-stock risk.
- Focus on the leaders: Stocks like Eli Lilly, Johnson & Johnson, and AbbVie could drive the rally.
- Watch the technicals: Monitor XLV’s support levels and key indicators like Williams %R for confirmation.
- Time your entry: Wait for early signs of strength, like consecutive days of gains, to avoid catching a falling knife.
Personally, I’d lean toward a mix of XLV and selective bets on its top holdings. The ETF provides stability, while individual stocks offer higher upside if they break out. What’s your take—ready to dive into health care, or are you waiting for more confirmation?
Risks to Keep in Mind
No investment is a slam dunk, and health care stocks come with their own set of risks. Regulatory changes, drug pricing debates, and macroeconomic shifts could weigh on the sector. Plus, if the broader market turns bearish, even strong technical setups might falter. Here’s a quick rundown of what to watch:
| Risk Factor | Potential Impact |
| Regulatory Changes | Could pressure drugmakers’ profits |
| Market Downturn | May delay sector recovery |
| Weak Earnings | Could derail individual stock rallies |
Despite these risks, the technical setup and historical patterns make a compelling case for a June rebound. The key is to stay disciplined and avoid chasing momentum blindly.
The Bigger Picture: Why Health Care Matters
Health care isn’t just another sector—it’s a cornerstone of the economy. From innovative drugs to medical devices, this industry touches lives daily. Perhaps the most exciting aspect is its resilience. Even in tough markets, people need health care, making it a defensive sector with long-term appeal. Right now, with valuations looking attractive after May’s sell-off, it’s hard not to get a little excited about the potential.
Health care stocks offer a unique blend of stability and growth. When the charts align, it’s a powerful combination.
– Market strategist
As we head into June, the question isn’t whether health care stocks will recover—it’s how big the bounce could be. With XLV at key support and its top holdings showing early signs of life, the stars seem to be aligning. But markets love to keep us on our toes, so stay sharp and keep those charts handy.
Word count: ~3,200 words
